GILOTRIF: payments to doctors
Payments that named GILOTRIF as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.1M
- Providers
- 5,197
- Transactions
- 14,840
- Average per transaction
- $72
The per-transaction average — $72 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,197 providers the average total is $206, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $981,921 | 91.9% |
| Boehringer Ingelheim International GmbH | $73,217 | 6.9% |
| Boehringer Ingelheim Pharma GmbH & Co.kg | $9,854 | 0.9% |
| Boehringer Ingelheim S.A. | $1,950 | 0.2% |
| Nippon Boehringer Ingelheim Co., Ltd. | $1,200 | 0.1% |